; Glioma (n=153), Thyroid (n=501); Lung (n=994); Liver (n=365); Pancreas (n=176); Head/Neck (n=499); Stomach (n=354); Urothelial (n=406); Renal (n=877); Prostate (n=494); Testis (n=134); Breast (n=1075); Cervical (n=291); Ovarian (n=373); Endometrial (n=541); Melanoma (n=102). Median, edges of the box with 25 th and 75 th percentiles and extremes are represented. b quantification of mRNA expression levels in CRC (n=210) and normal mucosa (n=20) from TCGA for a subset of immune-related genes enriched in colorectal cancer. c Heat map of differentially expressed genes deriving from the immune signature illustrating that CRCs from different datasets can be splitted in LY6G6D-low and high as compared to other genes. Red denotes high mRNA expression; green denotes low mRNA expression. Figure S4 . Prognostic significance of immune inhibitor molecules in CRC . a overall survival analysis in relation to LY6G6D IHC in CRC specimens. b The Kaplan-Meier overall survival analysis for PDL1 and PD1 is shown. c high LY6G6D and CD15/FUT4 expression is associated with short overall survival also in dataset II. d A similar trend is observed in relation to disease progression.
The P values by log rank test. Figure S5 . EGFR-unresponsive CRC cell lines are highly sensitive to trametinib and moletotinib combination. a The indicated CRC cell lines were treated every day with different concentrations of ruxolitinib or trametinib for 96 hours and cell proliferation was evaluated by MTT assay. b Sensitivity of characterized CRC cells to an Informer Set of small molecules that best target STAT5 nodes. Left, the JAK/STATi momelotinib results among the most effective in targeting STAT5. Right, cancer-genomic alterations at STAT5 locus copy number alterations show a close dependency to momelotinib in CRC cell lines (https://portals.broadinstitute.org/ctrp/). c HT29 and SW620 with primary resistance to cetuximab, were treated every day with different concentrations of trametinib and momelotinib for 96 hours at a fixed drug ratio of 1:1 and cell proliferation was evaluated by MTT assay. The same CRC cell lines were exposed to the trametinib, cetuximab or with their combination at fixed drug ratio of 1:1. *P<0.05 **P<0.01 by student t test (three independent experiments). Figure S6 . Resistance to JAK/STAT inhibitors mediated by activation of ERK signaling . a SW620 cells were transfected with either specific siRNA targeting STAT5 or with a control (scrambled) and harvested at 24 and 48 hours after transfection. Western blots for STAT5 expression and other proteins was done as described in Materials and Methods. Right, western blots showing that pAKT is downregulated by momelotinib, whereas ERBB3 expression is not activated by the treatment with both trametinib or momelotinib. b Western blots showing that momelotinib or ruxolitinib treatment leads to the activation of ERKs signaling in different CRC cell lines. c Left, western blots showing that trametinib treatment down modulates CD15/FUT4 through inhibition of ERK activation. Right, western blot showing that STAT3 is activated by trametinib treatment in SW480 CRC cells. d The dataset GDS5029 confirms that other MEKi (selumetinib) did not affect the LY6G6D/STAT5 axis, *P<0.05 **P<0.01 by student t test.
